Treatment Planning

Fluorescence imaging can help the specialist in a more targeted assessment and management of infection

MolecuLight i:X recommended, as review of NICE guidance in new JoWC publication "Wound healing: what is the NICE guidance from the UK?" for the assessment of fluorescent bacteria in wounds.

69% of wounds had changes in treatment plans due to using the MolecuLight i:X

85% of wounds with wound bed preparation & high bacterial burden (>10⁴ CFU/g) were impacted by information provided by the i:X

53% of wounds involving antimicrobial stewardship & high bacterial burden (>10⁴ CFU/g) were impacted by information provided by the i:X

The Fluorescence imaging procedure was used to inform advanced wound therapies

Three cases are described in which fluorescence images provided information at the point-of-care

This information was used to guide use of antibiofilm agents, NPWT, and preparation of the wound bed for grafting

Fluorescence imaging was more accurate than clinical judgement in detecting elevated bacterial loads

$7,660 USD per patient was the estimated cost savings from using fluorescence imaging information

This information avoided the application of cellular tissue products on wounds with high levels of bacteria

9/10 wound care patients more appropriately triaged with fluorescence information

60% of these 9 patients would have been undertreated while 30% of patients were being overtreated

$1552 Single patient cost savings (USD) due to fluorescence evidence-based treatment plan changes

Wounds were assessed for CSS & fluorescence images were then acquired to determine presence of moderate-to-heavy bacterial loads

Sensitivity of fluorescence imaging was 3-fold higher than CSS (72% vs 22%; p=0.002)

Fluorescence imaging information resulted in treatment plan modifications in 73% of study wounds